GeneDx Expands Exome Testing Access with Direct-to-Family Online Platform
Event summary
- GeneDx launched an online platform to streamline exome testing for children with developmental delay, intellectual disability, or epilepsy.
- The service allows families to initiate testing directly through GeneDx.com without traditional specialty-care referrals.
- Exome testing is recommended as a first-tier diagnostic tool by the American Academy of Pediatrics (AAP) for these conditions.
- Over 450,000 children in the U.S. live with epilepsy, and more than 1 million have intellectual disabilities.
- The offering is now available nationwide, subject to provider availability and state requirements.
The big picture
GeneDx's move aligns with broader industry trends toward democratizing genomic data access, addressing critical gaps in pediatric care. The launch comes amid growing recognition of exome sequencing as a first-tier diagnostic tool, supported by updated AAP guidelines. This strategic shift could position GeneDx to capture a larger share of the $10B+ U.S. genetic testing market.
What we're watching
- Market Penetration
- How GeneDx will scale this offering to reach underserved pediatric patients across the U.S.
- Regulatory Dynamics
- Whether state-specific requirements could impact the rollout or adoption of this service.
- Competitive Response
- The pace at which competitors may introduce similar direct-to-consumer genetic testing platforms.
Related topics